Quoin director granted options on 8,141 ADSs

Quoin Pharmaceuticals director Joseph Patrick Cooper reported receiving a new stock option grant.

Rhea-AI Filing Summary

Quoin Pharmaceuticals director Joseph Patrick Cooper reported receiving a new stock option grant. On February 4, 2026, he was awarded options to acquire 8,141 American Depositary Shares at an exercise price of $7.37 per ADS. Each ADS represents thirty-five ordinary shares of Quoin Pharmaceuticals.

The options vest over four years, with 20% becoming exercisable on each of February 4, 2027, 2028, and 2029, and the remaining 40% vesting on February 4, 2030. After this grant, Cooper beneficially owns 8,141 derivative securities directly.

Insider Trade Summary

Grant/Award: 8,141 shares

Grant/Award 1 txn

Insider Cooper Joseph Patrick

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	8,141	$0.00	$0.00

Holdings After Transaction: Share Option (Right to Buy) — 8,141 contracts (Direct)

Footnotes (2)

1. F1. The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.
2. F2. The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the latest Form 4 for Quoin Pharmaceuticals (QNRX) show?

The Form 4 reports director Joseph Patrick Cooper receiving options on 8,141 American Depositary Shares at a $7.37 exercise price. These options vest in staged annual installments from 2027 through 2030, and are held as a direct beneficial ownership position.

How many Quoin Pharmaceuticals (QNRX) options did Joseph Patrick Cooper receive?

Joseph Patrick Cooper received options on 8,141 American Depositary Shares of Quoin Pharmaceuticals. Each ADS represents thirty-five ordinary shares, according to the filing footnote, making the grant a derivative position linked to a significantly larger number of underlying ordinary shares.

What is the exercise price of Joseph Patrick Cooper’s Quoin (QNRX) options?

The options reported in the Form 4 have an exercise price of $7.37 per American Depositary Share. This price and the number of underlying securities are both stated in terms of ADSs, each representing thirty-five ordinary shares of Quoin Pharmaceuticals.

How do Joseph Patrick Cooper’s Quoin (QNRX) options vest over time?

The option vests in four annual installments. Twenty percent of the 8,141 ADS options vest on each of February 4, 2027, February 4, 2028, and February 4, 2029. The remaining forty percent vests on February 4, 2030, completing the vesting schedule.

Is Joseph Patrick Cooper’s Quoin (QNRX) option grant directly owned?

Yes. The Form 4 lists the 8,141 derivative securities as directly owned by Joseph Patrick Cooper. The filing classifies the security as a share option, with no indication of indirect ownership through another entity or person in the ownership field.

What type of security is reported in this Quoin Pharmaceuticals (QNRX) Form 4?

The filing reports a derivative security described as a “Share Option (Right to Buy).” It covers 8,141 American Depositary Shares of Quoin Pharmaceuticals, with a $7.37 exercise price and a multi-year vesting schedule extending from 2027 through 2030.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/06/2026 - 05:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cooper Joseph Patrick

(Last) (First) (Middle)

C/O QUOIN PHARMACEUTICALS LTD.,

42127 PLEASANT FOREST COURT

(Street)

ASHBURN VA 20148

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Quoin Pharmaceuticals, Ltd. [ QNRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$7.37(1)	02/04/2026		A		8,141(1)		(2)	02/04/2036	ADS	8,141(1)	$0	8,141(1)	D

Explanation of Responses:

1. The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

2. The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

	/s/ Joseph Cooper	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.